LENZ
LENZ Therapeutics, Inc.
$3.62
-0.03
(-0.82%)
Mkt Cap
113.19M
Volume
218,180
52W Range
3.35-42.98
Sector
Healthcare
Beta
1.63
EPS (TTM)
-4.09 USD
P/E Ratio
-5.61
Revenue (TTM)
21.48M USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 19.09M | 0 | 0 | 15.00M | 0 | 0 | 0 |
| Net Income | (82.13M) | (49.77M) | (69.97M) | (10.81M) | (70.76M) | (68.37M) | (109,000) |
| EPS | -2.85 | -2.34 | -15.30 | -12.89 | -8.54 | -8.24 | -0.01 |
| Free Cash Flow | (70.00M) | (59.86M) | (60.41M) | (94.57M) | (58.59M) | (10.27M) | (19,000) |
| FCF / Share | -2.43 | -2.81 | -7.42 | -12.06 | -7.07 | -1.24 | -0.00 |
| Operating CF | (69.17M) | (59.39M) | (60.38M) | (87.98M) | (52.85M) | (8.72M) | (19,000) |
| Total Assets | 305.88M | 215.30M | 70.38M | 46.95M | 18.34M | 22.56M | 6,000 |
| Total Debt | 815,000 | 1.38M | 329,000 | 250,000 | 0 | 0 | 2.21M |
| Cash & Equiv | 25.18M | 20.16M | 35.14M | 44.44M | 18.31M | 19.82M | 6,000 |
| Book Value | 284.34M | 204.08M | (92.71M) | (24.17M) | (14.21M) | (9.80M) | (2.22M) |
| Return on Equity | -0.29 | -0.24 | N/A | N/A | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.49M | 1.90M | 1.59M | 12.50M | 5.00M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (31.92M) | (41.49M) | (35.90M) | (16.70M) | (14.91M) | (14.62M) | (12.65M) | (10.21M) | (10.25M) | (16.65M) | (23.69M) | (18.88M) |
| EPS | -1.02 | -1.32 | -1.16 | -0.59 | -0.53 | -0.53 | -0.46 | -0.38 | -0.40 | -3.53 | -2.77 | -2.75 |
| Free Cash Flow | (38.73M) | (33.60M) | (33.06M) | (9.03M) | (11.75M) | (16.16M) | (9.23M) | (10.77M) | (15.93M) | (23.94M) | (20.97M) | (13.09M) |
| FCF / Share | -1.23 | -1.07 | -1.06 | -0.32 | -0.42 | -0.59 | -0.34 | -0.40 | -0.62 | -5.07 | -2.53 | -1.60 |
| Operating CF | (38.71M) | (33.58M) | (33.02M) | (8.59M) | (11.51M) | (16.05M) | (9.08M) | (10.58M) | (15.79M) | (23.94M) | (20.97M) | (13.09M) |
| Total Assets | 236.60M | 272.54M | 305.88M | 210.70M | 217.33M | 201.25M | 215.30M | 224.01M | 202.64M | 217.32M | 70.38M | 92.17M |
| Total Debt | 122,000 | 673,000 | 815,000 | 954,000 | 1.05M | 1.18M | 1.38M | 1.58M | 1.70M | 589,000 | 329,000 | 360,000 |
| Cash & Equiv | 24.21M | 24.77M | 25.18M | 25.40M | 37.61M | 23.04M | 20.16M | 41.05M | 84.03M | 200.36M | 35.14M | 42.85M |
| Book Value | 219.26M | 246.49M | 284.34M | 193.93M | 206.37M | 192.01M | 204.08M | 215.28M | 192.92M | 198.17M | (92.71M) | (69.57M) |
| Return on Equity | -0.15 | -0.17 | -0.13 | -0.09 | -0.07 | -0.08 | -0.06 | -0.05 | -0.05 | -0.08 | N/A | N/A |
LENZ News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Head to Head Comparison: Eloxx Pharmaceuticals (NASDAQ:ELOX) & LENZ Therapeutics (NASDAQ:LENZ)
These beaten-down stocks could bounce back in January, if history is any guide
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ